1 The Impact of Laterality on the Incidence and Prognosis of Epithelial Ovarian

- 2 Cancer
- 3
- 4 Yang Zhang¹, Yucong Huang¹, Jihui Kang², Shuzhong Yao¹, Langyu Gu^{3*}, Guofen
- 5 $Yang^{1*}$
- 6
- 7 ¹Department of Gynaecology, First Affiliated Hospital, Sun Yat-sen University,
- 8 Guangzhou 510060, Guangdong, China
- 9 ²Department of Pathology, First Affiliated Hospital, Sun Yat-sen University,
- 10 Guangzhou 510060, Guangdong, China
- ³State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-sen
- 12 University, Guangzhou, Guangdong 510275, China
- 13
- 14 *Correspondence:
- 15 Langyu Gu
- 16 guly6@mail.sysu.edu.cn; langyugu@gmail.com
- 17 Guofen Yang
- 18 yangguof@mail.sysu.edu.cn
- 19
- 20
- 21
- 22
- __
- 23
- 24
- 25
- 26
- 27
- 28
- 29

30 Abstract

31

32 Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, and 33 its mortality rate is the highest among gynecological malignancies. Despite numerous 34 factors being linked to the prognosis of EOC, the impact of ovarian laterality has 35 received limited attention. In this study, we comprehensively examined the effects of 36 laterality (left-right and bilateral-unilateral) on the incidence and prognosis of EOC, 37 with a particular focus on different subtypes. By utilizing a large clinical database, we 38 found that laterality differences primarily existed between unilateral and bilateral cases 39 in terms of both incidence and prognosis. Specifically, unilateral tumour development 40 was predominantly observed in patients with clear cell, endometrioid, and mucinous 41 ovarian cancer subtypes, while bilateral involvement was more common in serous 42 ovarian cancer. Laterality differences, reflecting disparities between the left and right 43 sides, were primarily observed in various stages of the overall population and within 44 specific EOC subtypes. Specifically, significant differences in EOC incidence between 45 the left and right sides at different stages were observed in the overall population, as 46 well as in clear cell, endometrioid, and serous ovarian cancer subtypes. Although no 47 significant differences in the incidence rate between the left and right sides were noted 48 for mucinous ovarian cancer, the prognosis was substantially better on the right side 49 compared to the left side. These findings underscore the importance of considering 50 ovarian laterality, both in terms of left-right and bilateral-unilateral aspects, as a critical 51 factor associated with the incidence and prognosis of EOC. Therefore, it should be 52 taken into account in clinical practice, particularly in the context of different tumour 53 stages and subtypes of EOC.

- 54
- 55 56
- 57 Key words :

58 epithelial ovarian cancer (EOC), laterality, subtypes, stage, incidence, prognosis

59

60 Introduction

Ovarian cancer is a significant concern in the field of gynaecology, with epithelial 61 ovarian cancer (EOC) being the most common type^{1,2}. It accounts for around 85% to 62 90% of all ovarian malignant tumours³. Despite advancements in treatment, the 5-year 63 survival rate for EOC remains below 50%, posing a serious threat to women's health⁴. 64 65 The standard treatment plan involves surgery and chemotherapy, followed by targeted therapy⁵. However, the prognosis of EOC patients can vary greatly due to the strong 66 individual heterogeneity among patients⁶. Therefore, it is crucial to improve the 67 68 diagnosis and prognosis of EOC in order to develop precision therapies for patients. 69

70 The prognosis of EOC is influenced by various factors including age, tumour grade and stage, histological type, and treatment^{7–9}. However, the impact of laterality, 71 72 or the side of the ovary affected by cancer, on EOC prognosis is often overlooked. 73 Some symmetrical organs affected by cancer, such as breast, testicles, and lungs, have 74 shown different prognosis outcomes depending on the side affected. For example, 75 patients with left testicular cancer, right lung cancer, and right breast cancer have been found to have better survival rates compared to those with contralateral disease $^{8,10-12}$. 76 77 Even among benign ovarian tumours, the incidence of mature teratoma varies significantly between the left and right sides¹³. However, few studies have analyzed the 78 79 impact of ovarian laterality on incidence and prognosis of EOC. Existing limited 80 studies have only compared the prognosis between unilateral and bilateral factors, without considering the differences between the left and right sides^{14,15}. Additionally, 81 82 EOC can be divided into different subtypes, including endometrioid, clear cell, serous 83 and mucinous ovarian cancers, with unique molecular pathways, clinic treatment, and survival rates¹⁶. The prognoses of these histological subtypes are thus cannot be 84 generalized¹⁷⁻²¹. Therefore, it remains unclear whether laterality should be considered 85 86 as an effective factor for incidence and prognosis of EOC, especially for different subtypes^{22–24}. 87

In this study, our aim is to utilize existing clinical databases to investigate the impact of ovarian laterality (both unilateral-bilateral and left-right) on the incidence and prognosis of EOC. Specifically, we intend to conduct a comprehensive analysis focusing on different histological subtypes of EOC. We hope to provide valuable insights into the prognostic significance of laterality in EOC and its implications for personalized treatment strategies.

95

96 Materials and Methods

97 1.Population

The study population consisted of patients diagnosed with EOC between 2010
and 2017 from the SEER (Surveillance, Epidemiology, and End Results) Research
Plus database, 18 Registries, Nov 2020 sub (2000-2018). The data was obtained using
SEER*Stat software (version 8.4.1.2) (https://seer.cancer.gov/seerstat/).

102

103 The inclusion criteria for the study were as follows: i) patients with a pathological 104 diagnosis of EOC based on the International Classification of Diseases for Oncology, 105 Third Edition (ICD-O-3) anatomical code (C56.9) and morphological codes (8310/3, 106 8313/3, 8380/3, 8381/3, 8382/3, 8383/3, 8441/3, 8460/3, 8461/3, 8470/3, 8471/3, 107 8480/3, 8481/3, and 8482/3); ii) availability of complete information on histological type, EOC stage (according to the seventh edition of the AJCC²⁵ or SEER combination 108 109 stage²⁶), and laterality; iii) active follow-up to accurately record the cause of death and 110 survival time. The exclusion criteria included cases where EOC confirmation through 111 cytological or histological means was lacking, as well as instances where grade 112 classification and race information were incomplete.

113

The analysis was conducted at two different levels: i) the overall population, which included 20,760 patients with EOC; ii) the four histological subtypes: clear cell ovarian cancer (N=1567), endometrioid ovarian cancer (N=3422), serous ovarian cancer (N=14145), mucinous ovarian cancer (N=1287). Details about the sampling information can be found in Figure 1.

119 2. Variables

120 The demographic and clinical characteristics of patients were defined as follows: 121 age ($< 60, \ge 60$), ethnicity (white, black, American Indian/Alaska Native AI and 122 Asian or Pacific Islander API), laterality (left, right and bilateral), FIGO stage (I II III 123 and IV), tumour grade (well, moderately, poorly and undifferentiated), and whether 124 there were chemotherapy and radiotherapy (Figure 1).



125

Figure 1 a. Flowchart of datasets with EOC and subtypes, as well as the inclusion criteria and the
exclusion criteria. b. Flowchart of statistical analysis in this study. EOC, epithelial ovarian cancer.
AUC, the area under the receiver operating characteristic curves.

129

130 3. Statistical analysis

131 Binomial test and Pearson's χ^2 test were performed to explore the difference of 132 the incidence between different lateralities. Univariate Cox regression analysis was 133 conducted to examine the impact of independent variables on the prognosis of EOC. 134 Multivariate Cox regression analysis was employed to construct a proportional 135 hazards model for tumour prognosis, and independent risk factors were evaluated with 136 a significance level set at p < 0.05. Survival curves were generated using the K-M 137 method to compare the differences in survival between different groups. Depending 138 on the results of the proportional hazards assumption, either Cox analysis or the 139 log-rank test was applied to assess the significance of the survival differences between 140 groups.

14	1
----	---

142 4. Construction and evaluation of prognostic risk model

143 Based on the independent risk factors for overall survival (OS) identified through 144 multivariate Cox regression analysis, nomograms were constructed using R software 145 (version 4.2.1). The concordance index (C-index) was utilized to evaluate the 146 accuracy of the nomogram models. A higher C-index indicates a more accurate 147 predictive model. The area under the receiver operating characteristic curve (AUC) 148 was used to assess the discriminative ability of the model. A higher AUC value 149 (closer to 1) indicates better predictive performance of the model. The bootstrap 150 method was employed for internal verification through 200 repeated samplings, and a 151 calibration plot was produced. A higher level of agreement between the predicted and 152 actual survival rates indicates a higher level of model compliance. 153 154 **Results** 155 **1.** Lateral incidence comparisons

156 1. The overall distribution pattern of laterality for EOC

157

158 20,760 patients with EOC were included in the study in total, including 5965 159 (28.7%) patients with left EOC, 6097 (27.4%) patients with right EOC, and 8698 160 (41.9%) patients with both ovaries. The incidence of unilateral EOC is significantly 161 higher than the one of bilateral in the overall population (unilateral vs. bilateral = 162 vs. 8698(41.9%), p < 0.001). Among the unilateral EOC, 5965 12062(58.1%) 163 patients (49.5%) were left and 6097 patients (50.5%) were right, indicating that there 164 is no significant difference in the overall incidence rate between the left and right 165 sides. However, there were significant differences between the left and right incidence 166 at different stages (p = 0.002). Further pairwise comparison indicates that this 167 difference was mainly observed in stage III (Left 47.2% vs Right 52.8%) and stage II 168 (Left 52.2% vs Right 47.8%). (Table 1)

170 We also characterized the distribution patterns of four subtypes of EOC in the 171 overall population. The results revealed that unilateral tumor pathogenesis 172 predominated in patients with clear cell (unilateral vs bilateral = 1385 (88.4%) vs 182 173 (11.6%), p < 0.001), endometrioid (unilateral vs bilateral = 2892 (84.5\%) vs 530 174 (15.5%), p < 0.001), and mucinous ovarian cancers (unilateral vs bilateral = 1483 175 (91.2%) vs 143 (8.8%), $p \le 0.001$), whereas bilateral involvement was more common in 176 serous ovarian cancer (unilateral vs bilateral = 6302 (44.6%) vs 7843 (55.4%), $p \leq$ 177 0.001) (Table 1).

178

179 **Table 1** Clinical characteristics and the overall distribution pattern of laterality for epithelial ovarian

180 cancer (EOC)

Clinical Characteri	stics	LEFT (n, %)	RIGHT (n, %)	P-value	Unilateral (n, %)	Bilateral (n, %)	P-value
	Total	5965(49.5%)	6097(50.5%)	0.233ª	12062(58.1%)	8698(41.9%)	< 0.001 ^a
	< 60	2885(49.3%)	2961(50.7%)	o o as h	5846(58.7%)	4107(41.3%)	o o g ch
Age	≥ 60	3080(49.5%)	3136(50.5%)	0.8278	6216(57.5%)	4591(42.5%)	0.0765
	White	4868(49.6%)	4952(50.4%)		9820(57.4%)	7296(42.6%)	
D	Black	398(48.3%)	426(51.7%)	0.102h	824(56.6%)	631(43.4%)	< 0.001h
Race recode	AI^*	52(61.9%)	32(38.1%)	0.1035	84(57.9%)	61(42.1%)	< 0.001°
	API*	647(48.5%)	687(51.5%)		1334(65.3%)	710(34.7%)	
	Ι	1105(50.8%)	1070(49.2%)		2175(85.1%)	381(14.9%)	< 0.001 ^b
a 1*	II	1162(48.3%)	1245(51.7%)	0.374 ^b	2407(71.7%)	950(28.3%)	
Grade	III	2027(49.2%)	2092(50.8%)		4119(52.2%)	3779(47.8%)	
	IV	1671(49.7%)	1690(50.3%)		3361(48.4%)	3588(51.6%)	
	Ι	2634(50.4%)	2588(49.6%)		5222(90.4%)	555(9.4%)	< 0.001 ^b
n. *	II	802(52.2%)	733(47.8%)		1535(69.8%)	665(30.2%)	
stage	III	1775(47.2%)	1984(52.8%)	0.0025	3759(42.5%)	5083(57.5%)	
	IV	754(48.8%)	792(51.2%)		1546(39.2%)	2395(60.8%)	
	No/Unknown	5893(49.5%)	6016(50.5%)		11909(58.0%)	8619(42.0%)	o o reh
Radiotherapy	Yes	72(47.1%)	81(52.9%)	0.551%	153(65.9%)	79(34.1%)	0.015 ^b
Chemotherapy	No/Unknown	1692(48.4%)	1802(51.6%)	0.450	3494(76.3%)	1088(23.7%)	
	Yes	4273(49.9%)	4295(50.1%)	0.150%	8568(53.0%)	7610(47.0%)	< 0.001
	clear cell	717(51.8%)	668(48.2%)	0.197ª	1385(88.4%)	182(11.6%)	< 0.001 ^a
	endometrioid	1439(49.8%)	1453(50.2%)	0.809 ^a	2892(84.5%)	530(15.5%)	< 0.001 ^a
histological Type	serous	3079(48.9%)	3223(51.1%)	0.072 ^a	6302(44.6%)	7843(55.4%)	< 0.001 ^a
	mucinous	730(49.2%)	753(50.8%)	0.568 ^a	1483(91.2%)	143(8.8%)	< 0.001 ^a

¹⁸¹

182 *AI: American Indian/Alaska Native; API: Asian or Pacific Islander; Grade I: well differentiated, 183 Grade II: Moderately differentiated, Grade III: Poorly differentiated, Grade IV: Undifferentiated or 184 anaplastic. Stage I: Tumour confined to ovaries or fallopian tube(s), Stage II: Tumour involves 1 or 185 both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer, Stage 186 III: Tumour involves 1 or both ovaries or fallopian tubes, or peritoneal cancer, with cytologically or

187 histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the

- 188 retroperitoneal lymph nodes, Stage IV: Distant metastasis excluding peritoneal metastases.
- 189 a. Binomial test
- 190 b. Pearson \Box s χ^2 test
- 191
- 192 2. The distribution pattern of laterality for different subtypes of EOC
- 193

194 The distribution patterns of laterality in the four subtypes of EOC were further 195 characterized, considering the varied clinical characteristics and molecular 196 mechanisms of each subtype (Table 2). In clear cell ovarian cancer, the difference in 197 incidence between unilateral and bilateral cases was primarily observed among 198 different stages, while the distinction between left and right incidence was mainly 199 observed among different races. For both endometrioid and serous ovarian cancers, 200 the primary disparity lied in the incidence rates between unilateral and bilateral cases, 201 as significant differences were observed in almost all subgroups, except for patients 202 who underwent radiotherapy. On the other hand, the discrepancy between left and 203 right incidence were primarily evident among different stages. In mucinous ovarian 204 cancer, there were no significant differences in the incidence rates between the left 205 and right sides among different populations.

206

207 **Table 2** Lateral incidence comparisons in four subtypes of epithelial ovarian cancer (EOC)

	LEFT (n, %)	RIGHT (n, %)	P-value	Unilateral (n, %)	Bilateral (n, %)	P-value
Total						
Clear cell						
Age□60	435(53.1%)	384(46.9%)	0.000	819(87.3%)	119(12.7%)	0.1068
Age≥60	282(49.8%)	284(50.2%)	0.228	566(90.0%)	63(10.0%)	0.106
White	549(53.3%)	481(46.7%)		1030(88.9%)	128(11.1%)	
Black	23(37.7%)	38(62.3%)	o oo th	61(82.4%)	13(17.6%)	0.221h
AI^*	6(75.0%)	2(25.0%)	0.034°	8(88.9%)	1(11.1%)	0.321
API [*]	139(48.6%)	147(51.4%)		286(87.7%)	40(12.3%)	
Grade I	8(44.4%)	10 (55.6%)		18(94.7%)	1(5.3%)	
Grade II	74(51.7%)	69(48.3%)	0.915 ^a	143(92.9%)	11(7.1%)	0.154 ^b
Grade III	375(52.3%)	342(47.7%)		717(87.0%)	107(13.0%)	

Grade IV	260(51.3%)	247(48.7%)		507(88.9%)	63(11.1%)	
Stage I	477(52.7%)	428(47.3%)		905(96.6%)	32(3.4%)	
Stage II	89(52.7%)	80(47.3%)	0.5648	169(88.5%)	22(11.5%)	
Stage III	115(49.6%)	117(50.4%)	0.564	232(72.0%)	90(28.0%)	0.001
Stage IV	36(45.6%)	43(54.4%)		79(67.5%)	38(32.5%)	
No/Unknown Radiotherapy	703(51.7%)	657(48.3%)	0.6608	1360(88.4%)	179(11.6%)	1.000%
Radiotherapy treated	14(56.0%)	11(44.0%)	0.669*	25(89.3%)	3(10.7%)	1.000*
No/Unknown Chemotherapy	143(51.1%)	137(48.9%)	0.70.48	280(91.2%)	27(8.8%)	0.0058
Chemotherapy treated	574(51.9%)	531(48.1%)	0.794	1105(87.7%)	115(12.3%)	0.085
Endometrioid						
Age□60	879(49.5%)	898(50.5%)	0.601a	1777(82.7%)	372(17.3%)	<0.001 ^a
Age≥60	560(50.2%)	555(49.8%)	0.091	1115(87.6%)	158(12.4%)	<0.001
White	1190(50.1%)	1183(49.9%)		2373(85.2%)	412(14.8%)	
Black	65(45.5%)	78(54.5%)	0 102 ^a	143(76.9%)	43(23.1%)	0.010 ^b
AI^*	14(73.7%)	5(26.3%)	0.102	19(79.2%)	5(20.8%)	0.019
API [*]	170(47.6%)	187(52.4%)		357(83.6%)	70(16.4%)	
Grade I	609(51.0%)	584(49.0%)		1193(91.5%)	111(8.5%)	
Grade II	520(48.6%)	550(51.4%)	0.620 ^a	1070(84.9%)	190(15.1%)	$\Box 0.001^{a}$
Grade III	258(48.8%)	271(51.2%)	0.020	529(72.6%)	200(27.4%)	
Grade IV	52(52.0%)	48(48.0%)		100(77.5%)	29(22.5%)	
Stage I	989(49.1%)	1024(50.9%)		2013(92.0%)	176(8.0%)	
Stage II	247(53.8%)	212(46.2%)	0.043a	459(79.5%)	118(20.5%)	$\Box 0.001^{a}$
Stage III	148(45.5%)	177(54.5%)	0.045	325(66.2%)	166(33.8%)	
Stage IV	55(57.9%)	40(42.1%)		95(57.6%)	70(42.4%)	
No/Unknown Radiotherapy	1411(49.8%)	1423(50.2%)	0.820ª	2834(84.7%)	513(15.3%)	0.082a
Radiotherapy treated	28(48.3%)	30(51.7%)	0.820	58(77.3%)	17(22.7%)	0.082
No/Unknown Chemotherapy	567(47.7%)	622(52.3%)	0.063ª	1189(90.6%)	124(9.4%)	$\Box 0.001^{a}$
Chemotherapy treated	872(51.2%)	831(48.8%)	0.005	1703(80.7%)	406(19.3%)	
Serous						
Age□60	1073(48.3%)	1147(51.7%)	0 530 ^a	2220(38.6%)	3529(61.4%)	<0.001 ^a
Age≥60	2006(49.1%)	2076(50.9%)	0.557	4082(48.6%)	4314(51.4%)	<0.001
White	2552(48.8%)	2680(51.2%)		5232(44.0%)	6646(56.0%)	
Black	254(50.2%)	252(49.8%)	0 774 ^a	506(47.6%)	557(52.4%)	0.0508
AI^*	27(54.0%)	23(46.0%)	0.774	50(47.6%)	55(52.4%)	0.050
API [*]	246(47.9%)	268(52.1%)		514(46.8%)	585(53.2%)	
Grade I	149(51.0%)	143(49.0%)		292(56.2%)	228(43.8%)	
Grade II	285(48.6%)	302(51.4%)	0.787 ^a	587(45.8%)	696(54.2%)	$\Box 0.001^{a}$
Grade III	1315(48.3%)	1407(51.7%)		2722(44.3%)	3428(55.7%)	

Grade IV 1330(49.2%) 1371(50.8%) 2701(43.6%) 3491(56.4%) Stage I 559(51.6%) 525(48.4%) 1084(77.3%) 319(22.7%) Stage II 430(51.4%) 836(62.6%) 499(37.4%) 406(48.6%) 0.041^{a} $\Box 0.001^{a}$ 3073(39.2%) Stage III 1455(47.3%) 1618(52.7%) 4771(60.8%) Stage IV 635(48.5%) 674(51.5%) 1309(36.7%) 2254(63.3%) 3052(48.9%) 7785(55.5%) No/Unknown Radiotherapy 3193(51.1%) 6245(44.5%) 0.821^a 0.278^{a} Radiotherapy treated 27(47.4%) 30(52.6%) 57(49.6%) 58(50.4%) 537(47.5%) No/Unknown Chemotherapy 594(52.5%) 1131(55.8%) 897(44.2%) 0.306^a $\Box 0.001^{a}$ Chemotherapy treated 2542(49.2%) 2629(50.8%) 5171(42.7%) 6946(57.3%) Mucinous 87(19.8%) Age□60 498(48.3%) 532(51.7%) 1030(28.2%) 0.309^{a} 0.034^{a} Age≥60 232(51.2%) 221(48.8%) 453(30.0%) 56 (22.1%) White 577(48.7%) 608(51.3%) 1185(91.5%) 110(8.5%) Black 56(49.1%) 58(50.9%) 114(86.4%) 18(13.6%) 0.573^b 0.179^{a} AI^* 2(28.6%) 0(0.0%)5(71.4%) 7(100.0%) API^{*} 92(52.0%) 85(48.0%) 177(92.2%) 15(7.8%) Grade I 339(50.4%) 333(49.6%) 672(94.2%) 41(5.8%) Grade II 607(92.0%) 53(8.0%) 283(46.6%) 324(53.4%) 0.353^a $\Box 0.001^{a}$ Grade III 79(52.3%) 72(47.7%) 151(77.4%) 44(22.6%) Grade IV 29(54.7%) 24(45.3%) 53(91.4%) 5(8.6%) Stage I 609(49.9%) 611(50.1%) 1220(92.8%) 28(2.2%) Stage II 36(50.7%) 26(26.8%) 35(49.3%) 71(73.2%) 0.535^a $\Box 0.001^{a}$ Stage III 57(44.2%) 72(55.8%) 129(69.7%) 56(30.3%) Stage IV 28(44.4%) 35(44.6%) 63(65.6%) 33(34.4%) No/Unknown Radiotherapy 727(49.5%) 743(50.5%) 1470(91.2%) 142(8.8%) 0.058^{a} 1.000° 13(92.9%) Radiotherapy treated 3(23.1%) 10(76.9%) 1(7.1%)No/Unknown Chemotherapy 445(49.8%) 449(50.2%) 894(95.7%) 40(4.3%) 0.601^a $\Box 0.001^{a}$

208

209 2. Prognosis evaluation

Chemotherapy treated

210	2.1 Bilateral had a worse prognosis than unilateral EOC in the overall population
211	Age, ethnicity, laterality (left, right and bilateral), FIGO stage, tumour grade and

304(51.2%)

589(91.2%)

103 (8.8%)

285(48.4%)

212 whether there was chemotherapy and radiotherapy were included as independent

213 prognostic factors. Multivariate cox regression analysis showed that older age (HR =

214 1.526, p < 0.001), bilateral tumours (HR = 1.114, p < 0.001), black race (HR = 1.271,

p < 0.001), higher grade and higher stage and radiotherapy (HR = 1.435, p < 0.001) 215

medRxiv preprint doi: https://doi.org/10.1101/2023.08.26.23294664; this version posted August 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

216	were independent risk factors for EOC, and chemotherapy (HR = 0.534, $p < 0.001$)
217	was independent favourable factors for EOC (Table 3). For the variable of laterality,
218	there was no significant difference in prognosis between patients with right-sided and
219	left-sided EOC, with a hazard ratio of 0.987 ($p = 0.692$, 95%CI: 0.925-1.053) (Table
220	2). Patients with bilateral ovarian cancer, however, had a worse prognosis than those
221	with unilateral ovarian cancer, with a hazard ratio of 1.120 ($p < 0.001$, 95%CI:
222	1.070-1.173).

223

<u>- 1 -</u>

224 Table 3 Univariable and multivariable analyses of clinicopathological characteristics as predictors of

			Univariable analysis		Multivariable analysis			
characteristics		HR	95% CI	P-value	HR	95% CI	P-value	
Age	≥60 years	1.922	1.838-2.011	< 0.001*	1.526	1.458-1.598	< 0.001*	
	Left	Reference						
Laterality	Right	1.017	0.953-1.085	0.608	0.989	0.927-1.055	0.730	
	Bilateral	1.941	1.837-2.050	< 0.001*	1.114	1.052-1.179	□0.001*	
	White	Reference						
	Black	1.350	1.248-1.460	< 0.001*	1.271	1.175-1.375	< 0.001*	
Race recode	AI	0.978	0.754-1.270	0.870	1.004	0.773-1.303	0.977	
	API	0.832	0.769-0.901	< 0.001*	0.975	0.901-1.056	0.537	
	Ι	Reference						
	II	2.087	1.840-2.366	< 0.001*	1.574	1.385-1.788	< 0.001*	
Grade	III	4.563	4.080-5.102	< 0.001*	2.083	1.850-2.345	< 0.001*	
	IV	4.597	4.107-5.146	< 0.001*	2.025	1.795-2.284	< 0.001*	
	Ι	Reference						
G .	II	2.329	2.080-2.607	< 0.001*	2.173	1.934-2.441	< 0.001*	
Stage	III	5.866	5.411-6.360	< 0.001*	5.182	4.732-5.676	< 0.001*	
	IV	9.127	8.381-9.939	< 0.001*	7.854	7.131-8.649	< 0.001*	
Radiotherapy	YES	1.249	1.036-1.507	0.02^{*}	1.435	1.190-1.731	< 0.001*	
Chemotherapy	YES	1.206	1.141-1.275	< 0.001*	0.534	0.504-0.566	< 0.001*	

225 overall survival (OS) for epithelial ovarian cancer (EOC).

226 *p < 0.05. AI: American Indian/Alaska Native; API: Asian or Pacific Islander;

227

228 We further divided EOC patients into different subgroups according to laterality,

229 i.e., unilateral vs. bilateral. The KM plot was used to compare survival differences

230 between groups. Again, results showed that the unilateral EOC had a significant



231 prognostic advantage over bilateral EOC (p < 0.0001) (Figure 2).

Figure 2 Unilateral vs. bilateral Kaplan-Meier survival curves in overall population. The median survival for bilateral tumours is 50 months, while the median survival for unilateral tumours is over 100 months and still not reached.

237

233

232

Independent risk factors filtrated based on multivariate cox regression analysis were used to construct nomograms for 1-, 3- and 5-year OS (Figure 3a). The C-index of the nomogram was 0.724 [95% confidence interval (CI): 0.718–0.730]. The AUCs of the 1-, 3-, and 5-year nomogram models were 0.751, 0.752, and 0.775, respectively. The calibration plots all demonstrated good agreement between the predictive values of OS for 1-, 3- and 5-year survival and the actual survival probability (Figure 3b, Figure 3c).





Figure 3 a. Based on the independent risk factors screened by multivariate cox regression analysis of the overall population, a nomogram was drawn to predict the survival rate of 1-, 3-, and 5-years respectively. b. The area under the receiver operating characteristic curves (AUCs) of the 1-, 3-, and 5-year were devoted to evaluating the discriminative ability of the nomogram models. c. The calibration plots of OS for 1-, 3- and 5-year.

252

253 2.2 Bilateral EOC has a significantly worse prognosis than unilateral EOC, especially254 in stage II

255

When we focused on the prognosis effects of laterality on subgroup population divided by significant variables obtained from multivariate cox regression analysis above, bilateral EOC exhibited a significantly worse prognosis than unilateral EOC in most subgroups, except advanced EOC (Stage III/IV). Especially in stage II, that bilateral EOC has a significantly worse prognosis than unilateral EOC which is not mentioned in the FIGO staging system²⁷. To account for multiple testing, two-sided *p* values were adjusted according to the method of Benjamini/Hochberg (B/H) to

- 263 control the false discovery rate (FDR). An association was considered to be
- 264 statistically significant, if its corresponding B/H-adjusted p value was below 0.05,
- corresponding to an FDR of 5%. (Figure 4).



266

Figure 4 a. Subgroup analysis Unilateral vs. Bilateral in overall population; The last two columns list
the unadjusted and adjusted p values according to Benjamini/Hochberg (BH), respectively. All 0.001
refers to less than 0.001.b. Survival curve between Unilateral and Bilateral in Stage II.

270

271 2.3 The prognosis of right-side is worse than the left-side in mucinous ovarian cancer 272 In each subtype of histology, the effect of laterality on tumour prognosis was 273 mostly consistent with the effect in the overall population we identified above (Table 274 3), that is patients with left and right ovarian cancer were nearly overlap with no 275 statistical significance, but the unilateral EOC has a significant prognostic advantage 276 over bilateral EOC (Table 4 and Supplementary File 1). However, in patients with 277 mucinous ovarian cancer, the right-to-left prognostic hazard ratio was 0.745 (p = 278 0.015, 95% CI 0.587 to 0.945) (Table 4), indicating that right mucinous ovarian cancer 279 exhibited a better prognosis than left.

281 Table 4 Univariable and multivariable analyses of overall survival (OS) for mucinous ovarian cancer

Characteristics			Univariable analysi	s	Multivariable analysis		
		HR	95% CI	P-value	HR	95% CI	P-value
Age (60y)		1.982	1.614-2.434	< 0.001*	1.751	1.420-2.161	< 0.001*
Laterality	Left	Reference					
	Right	0.872	0.689-1.104	0.256	0.745	0.587-0.945	0.015*

	Bilateral	4.715	3.628-6.127	< 0.001*	1.303	0.978-1.736	0.07
	White	Reference					
	Black	1.776	1.297-2.433	< 0.001*			
Race recode	AI	1.910	0.612-5.958	0.265			
	API	0.868	0.614-1.228	0.423			
	Ι	Reference					
Grade	Π	1.472	1.147-1.889	0.002	1.264	0.983-1.625	0.068
	III	4.141	3.146-5.450	< 0.001*	2.164	1.626-2.881	< 0.001*
	IV	3.082	1.949-4.875	< 0.001*	2.640	1.663-4.191	< 0.001*
	Ι	Reference					
G .	Π	1.888	1.599-2.230	< 0.001*	2.345	1.538-3.577	< 0.001*
Stage	III	4.307	3.767-4.924	< 0.001*	7.858	6.033-10.236	< 0.001*
	IV	6.614	5.767-7.584	< 0.001*	16.607	12.204-22.598	< 0.001*
Radiotherapy	YES	5.321	2.833-9.992	< 0.001*			
Chemotherapy	YES	2.089	1.696-2.573	< 0.001*			

282 *p < 0.05.

283

284 Based on the result of COX proportional hazards model of mucinous ovarian 285 cancer, we construct the nomogram (Fig 5a). The C-index of the predictive OS 286 nomogram of mucinous ovarian cancer was 0.818 [95% confidence interval (CI): 287 0.794-0.842]. The AUCs of the 1-, 3-, and 5-year nomogram models were 0.870, 288 0.850, and 0.815, respectively. The calibration plots also demonstrated excellent 289 agreement between the predictive values of OS for 1-, 3- and 5-year survival and the 290 actual survival probability (Fig 5b, Fig 5c). This predictive OS nomogram of 291 mucinous ovarian cancer shows higher consistency than of overall population. And 292 the AUCs were closer to 1, showing good prediction performance.





Figure 5 a. Based on the independent risk factors screened by multivariate cox regression analysis of the mucinous ovarian cancer, a nomogram was drawn to predict the survival rate of 1-, 3-, and 5-years respectively. b. The area under the receiver operating characteristic curves (AUCs) of the 1-, 3-, and 5-year were devoted to evaluating the discriminative ability of the nomogram models. c. The calibration plots of OS for 1-, 3- and 5-year.

299

300 Discussion

301

302 This study investigated the impact of ovarian laterality (unilateral vs. bilateral, 303 left-side vs. right-side) on both incidence and prognosis of EOC in the overall 304 population and among different subtypes. In the overall population, the laterality 305 difference primarily occurred between unilateral and bilateral cases. The bilateral 306 incidence rate was lower than that of unilateral cases, and bilateral prognosis was worse 307 than unilateral prognosis in the overall population, which are as expected. Notably, the 308 impact of laterality on incidence rate varied among different EOC subtypes. Serous 309 ovarian cancer predominantly occurred bilaterally, while the other three subtypes

310 primarily occurred on the unilateral side, consistent with previous reports. Initially, we 311 hypothesized that this difference may be due to the bilateral origins of serous ovarian 312 cancer. However, genetic studies on bilateral invasive ovarian tumours have shown that 313 the majority of cases of serous ovarian cancer are monoclonal, representing spread from a single ovarian site 28 . Then we proposed that the discrepancy could be attributed 314 315 to the varying frequency of different subtypes at the initial diagnosis stage. Our dataset 316 revealed that most serous ovarian cancer cases were diagnosed at advanced stages, such 317 as stage III (51%) or IV (29%). This aligns with clinical practice, as serous ovarian 318 cancer is typically challenging to detect at an early stage, due to its small size at the 319 early stages, making it difficult to develop symptoms without metastasis or 320 complications. Additionally, serous ovarian cancer cells are mostly high-grade, type II 321 epithelial, which are aggressive and cause the disease to progress rapidly⁵. 322 Consequently, serous ovarian cancer are often detected at advanced stages, which could 323 explain why it is predominantly detected bilaterally in our study. In contrast, the 324 majority (58% to 64%) of endometrioid, mucinous, and clear cell ovarian cancer cases in the dataset were diagnosed at earlier stages, such as stage $I^{16,29}$. This can be attributed 325 326 to the fact that endometrioid and clear cell ovarian cancers are endometriosis-related 327 diseases, which are relatively easier to detect early due to symptoms such as 328 dysmenorrhea. Additionally, the larger size of mucinous ovarian cancer also facilitates early diagnosis compared to serous ovarian cancer³⁰. 329

330

331 It is noteworthy that the incidence rate between the left and right sides significantly 332 varied among different stages of EOC in the overall population. Furthermore, 333 significant differences were also observed in the incidence rates between the left and 334 right sides, as well as between unilateral and bilateral cases among different stages in 335 many EOC subtypes. Moreover, we identified stage as an important factor influencing 336 the disparities in prognosis between unilateral and bilateral cases. All these results 337 consistently demonstrated a significant relationship between stage and the differences 338 in lateral incidence rates. As we know that tumours at different stages often have 339 distinct genetic characteristics and clinical features⁵. The FIGO staging system is

widely used for gynaecological malignancies, including EOC, but it does not adequately consider the laterality of the ovary, except in stage I where unilateral or bilateral involvement is considered as a prognostic factor²⁷. Our study revealed that ovarian laterality, both for unilateral-bilateral and left-right comparisons, has a significant impact on both incidence and prognosis of EOC at different stages.

345

346 The impact of laterality on the prognosis of different EOC subtypes also varies, 347 particularly for mucinous ovarian cancer. We observed that the prognosis on the right 348 side was significantly better than that on the left side for mucinous ovarian cancer. 349 While univariate Cox regression analysis revealed no significant difference in 350 prognosis between the left and right sides, multivariate Cox regression analysis 351 demonstrated a significant difference (p < 0.05). The inconsistency between these 352 results may be attributed to the correlation between other confounding factors and 353 laterality in the univariate analysis, which masks the true effect of laterality. However, 354 multivariate analysis accounted for this effect by including other variables, revealing 355 laterality as an independent factor affecting mucinous ovarian cancer prognosis. To the 356 best of our knowledge, no literature has reported this phenomenon.

357

358 The reasons for the poorer prognosis on the left side compared to the right side of 359 mucinous ovarian cancer require further investigation. Here, we can only offer some 360 inferences based on existing research findings. Primary mucinous ovarian cancer is a 361 rare malignancy, accounting for less than 3% of all EOC cases. Nearly 60% of 362 mucinous ovarian cancer cases are metastatic ovarian tumors, with the stomach or colorectum being the most common origin of metastasis^{24,30,31}. The lateral preference 363 364 for metastasis may be a related factor. Anatomical differences between the left and right hemipelvis could provide an explanation. Charles Chapron et al³². indicated that 365 366 the close anatomical relationship between the sigmoid colon and the left adnexa forms a 367 barrier to the pelvic diffusion of menstrual blood reflux. This has been used to explain 368 why deeply infiltrating endometriosis lesions are more commonly observed in the 369 posterior pelvic compartment and predominantly located on the left side. This

370 asymmetric anatomy of the pelvic cavity may also affect the direct spread and 371 implantation of cancer cells, thus potentially explaining why the prognosis on the left 372 side is poor for mucinous ovarian cancer. Furthermore, variations in venous structures 373 may also be a factor that affects the distant metastasis of cancer cells, consequently 374 influencing the prognosis. Hematogenous metastasis is one of the mechanisms of 375 distant metastasis in ovarian cancer tumors. The right ovarian reflux vein joins the inferior vena cava, while the left ovarian blood flows back into the renal vein³³. Due to 376 377 the thinness of the renal vein and its susceptibility to reflux obstruction, pelvic varices in the left ovary are more common³⁴. Lastly, differences in the invasive and metastatic 378 379 capacities of left and right mucinous ovarian cancer cells themselves may also 380 contribute to the disparity in prognosis. Further comprehensive research is necessary to 381 elucidate the underlying mechanisms related to the different prognosis between the left 382 and right sides of mucinous ovarian cancer.

383

384 We also found significant effects of age and race on the incidence rates and 385 prognostic differences between unilateral and bilateral cases, as well as between the left 386 and right sides, both in the overall population and across different subtypes. Indeed, 387 studies have reported the effects of age and race on disease incidence rates and prognosis. For instance, Lindsey A. Torre et al²⁹. demonstrated that API women have 388 389 the highest incidence rate of clear cell ovarian cancer and the lowest incidence rate of 390 serous ovarian cancer. Therefore, it is important to consider the impacts of age and race 391 on the laterality of incidence rates and prognosis in clinical practice.

392

To the best of our knowledge, our study is the first to systematically investigate the impact of laterality on the incidence and prognosis of EOC. Our results suggest that whether the tumour occurs unilaterally or bilaterally, the left-side or right-side, significantly influences the incidence and prognosis of EOC, particularly in different subtypes and stages. These findings should be taken into consideration in clinical practice.

400 Declarations

401 Ethics approval and consent to participate

- 402 Not applicable.
- 403 **Consent for publication**
- 404 Not applicable.

405 Availability of data and materials

- 406 Information about the data used in this study were included in this article and its
- 407 supplementary files.

408 **Competing interests**

409 The authors declare no competing interests.

410 Authors' Contributions

- 411 GY and LG conceived the study. YZ conducted the analyses. YZ, YH and JK
- 412 conducted data curation. SY and GY gave the funding supports. YZ and LG wrote the
- 413 manuscript and all authors commented on it.
- 414 Funding

415 This study was supported by the National Key R&D Program of China

416 (2022YFC2704200, 2022YFC2704201).

417 Acknowledgements

418 We thank Prof. Canwei Xia and Prof. Xia Shen for the valuable suggestions.

419

420 **Reference:**

421 1. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary,
422 fallopian tube, and peritoneum: 2021 update. *Int J Gynecol Obstet*.

423 2021;155(S1):61-85. doi:10.1002/ijgo.13878

424 2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN
425 Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
426 *CA Cancer J Clin.* 2021;71(3):209-249. doi:10.3322/caac.21660

- 427 3. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a
 428 proposed unifying theory. *Am J Surg Pathol.* 2010;34(3):433-443.
 429 doi:10.1097/PAS.0b013e3181cf3d79
- 4. Doherty JA, Peres LC, Wang C, Way GP, Greene CS, Schildkraut JM. Challenges
 and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. *Curr Epidemiol Rep.* 2017;4(3):211-220. doi:10.1007/s40471-017-0115-y
- 433 5. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet Lond* 434 *Engl.* 2019;393(10177):1240-1253. doi:10.1016/S0140-6736(18)32552-2
- 435 6. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review.
 436 *Cancer Biol Med.* 2017;14(1):9-32. doi:10.20892/j.issn.2095-3941.2016.0084
- 437 7. J B, Kd Y, Yz J, Zm S, Gh D. The effect of laterality and primary tumor site on
 438 cancer-specific mortality in breast cancer: a SEER population-based study. *PloS*439 *One*. 2014;9(4). doi:10.1371/journal.pone.0094815
- 8. Roychoudhuri R, Putcha V, Møller H. Cancer and Laterality: A Study of The Five
 Major Paired Organs (UK). *Cancer Causes Control*. 2006;17(5):655-662.
 doi:10.1007/s10552-005-0615-9
- 9. Negri F, De Giorgi A, Gilli A, et al. Impact of laterality and mucinous histology on
 relapse-free and overall survival in a registry-based colon cancer series. *Sci Rep.*2019;9(1):3668. doi:10.1038/s41598-019-40096-6
- 10. Rc B, R P, B K, Z E, R D, N E. Divergent Impact of Breast Cancer Laterality on
 Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of
 Tumor Localization in Future Outcomes. *J Clin Med.* 2020;9(6).
 doi:10.3390/jcm9061708
- 450 11. Weiss HA, Devesa SS, Brinton LA. Laterality of breast cancer in the United
 451 States. *Cancer Causes Control CCC*. 1996;7(5):539-543. doi:10.1007/BF00051887

452 12. Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided
453 versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab
454 in NCIC CO.17. *Eur J Cancer Oxf Engl 1990.* 2015;51(11):1405-1414.
455 doi:10.1016/j.ejca.2015.03.015

456 13. He X, Zhao X, Wang X, et al. Distinctive pattern of left–right asymmetry of
457 ovarian benign teratomas in Chinese population: a 12-year-long cross-sectional

458	study.	Arch	Gynecol	Obstet.	2021;303(3):729-737.
459	doi:10.10	07/s00404-020)-05864-0		

460 14. Bairi KE, Trapani D, Page CL, Saad A, Jarroudi OA, Afqir S. Exploring the
461 prognostic impact of tumor sidedness in ovarian cancer: A population-based
462 survival analysis of over 10,000 patients. *Cancer Treat Res Commun.*463 2022;33:100625. doi:10.1016/j.ctarc.2022.100625

- 464 15. Yamada Y, Mabuchi S, Kawahara N, Kawaguchi R. Prognostic significance of
 465 tumor laterality in advanced ovarian cancer. *Obstet Gynecol Sci.*466 2021;64(6):524-531. doi:10.5468/ogs.21176
- 467 16. Matz M, Coleman MP, Carreira H, et al. Worldwide comparison of ovarian cancer
 468 survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecol Oncol.*469 2017;144(2):396-404. doi:10.1016/j.ygyno.2016.11.019
- 470 17. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of
 471 epithelial ovarian cancer-shifting the paradigm. *Hum Pathol*. 2011;42(7):918-931.
 472 doi:10.1016/j.humpath.2011.03.003
- 473 18. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current
 474 clinical perspectives and future potential. *Clin Cancer Res Off J Am Assoc Cancer*475 *Res*. 2013;19(5):961-968. doi:10.1158/1078-0432.CCR-12-2243
- 476 19. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for
 477 pelvic serous carcinogenesis. *Curr Opin Obstet Gynecol.* 2007;19(1):3-9.
 478 doi:10.1097/GCO.0b013e328011a21f
- 479 20. Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology
 480 and molecular biology and their clinical implications. *Int J Gynecol Pathol Off J*481 *Int Soc Gynecol Pathol.* 2008;27(2):151-160. doi:10.1097/PGP.0b013e318161e4f5
- 482 21. Cho KR, Shih IM. OVARIAN CANCER. *Annu Rev Pathol.* 2009;4:287-313.
 483 doi:10.1146/annurev.pathol.4.110807.092246
- 484 22. Cao C, Yang X. The Prevalence, Associated Factors for Lung Metastases
 485 Development and Prognosis in Ovarian Serous Cancer Based on SEER Database.
 486 *Technol Cancer Res Treat.* 2020;19:1533033820983801.
 487 doi:10.1177/1533033820983801

488 23. Huang Y, Ming X, Li B, Li Z. Histological Characteristics and Early-Stage
489 Diagnosis Are Associated With Better Survival in Young Patients With Epithelial
490 Ovarian Cancer: A Retrospective Analysis Based on Surveillance Epidemiology
491 and End Results Database. *Front Oncol.* 2020;10. Accessed September 27, 2022.
492 https://www.frontiersin.org/articles/10.3389/fonc.2020.595789

493 24. Qi X, Xu L, Wang J, Yu J, Wang Y. Nomograms for primary mucinous ovarian

494 cancer: A SEER population-based study. J Gynecol Obstet Hum Reprod.
495 2022;51(7):102424. doi:10.1016/j.jogoh.2022.102424

496 25. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th
497 edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol.*498 2010;17(6):1471-1474. doi:10.1245/s10434-010-0985-4

499 26. National Institutes of Health. National Cancer Institute. Surveillance. 500 Epidemiology, and End Results Program. Statistical summaries: cancer stat fact 501 statistics review (CSR), 2013-2019. sheets (ovary) and cancer 502 https://seer.cancer.gov/statfacts/html/ovary.html

503 27. Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and
 504 primary peritoneal cancer and their clinical implications. *Ann Oncol Off J Eur Soc* 505 *Med Oncol.* 2017;28(suppl_8):viii8-viii12. doi:10.1093/annonc/mdx445

506 28. Tsao SW, Mok CH, Knapp RC, et al. Molecular genetic evidence of a unifocal
507 origin for human serous ovarian carcinomas. *Gynecol Oncol.* 1993;48(1):5-10.
508 doi:10.1006/gyno.1993.1002

509 29. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA
 510 Cancer J Clin. 2018;68(4):284-296. doi:10.3322/caac.21456

S11 30. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol Off J Eur Soc Med
 S12 Oncol. 2016;27 Suppl 1:i53-i57. doi:10.1093/annonc/mdw087

S13 31. Kurnit KC, Frumovitz M. Primary mucinous ovarian cancer: options for surgery
and chemotherapy. *Int J Gynecol Cancer Off J Int Gynecol Cancer Soc*. Published
online October 13, 2022:ijgc-2022-003806. doi:10.1136/ijgc-2022-003806

516 32. Chapron C, Chopin N, Borghese B, et al. Deeply infiltrating endometriosis:
517 pathogenetic implications of the anatomical distribution. *Hum Reprod Oxf Engl.*518 2006;21(7):1839-1845. doi:10.1093/humrep/del079

33. Gupta R, Gupta A, Aggarwal N. Variations of Gonadal Veins: Embryological
Prospective and Clinical Significance. J Clin Diagn Res JCDR.
2015;9(2):AC08-AC10. doi:10.7860/JCDR/2015/9493.5578

522 34. Riva N, Calleja-Agius J. Ovarian Vein Thrombosis: A Narrative Review.
523 *Hamostaseologie*. 2021;41(4):257-266. doi:10.1055/a-1306-4327

524